RxDoctor Payments Data

Todd Teigeler, MD

Clinical Cardiac Electrophysiology · Winchester, VANPI 1982016614

Payments from drug & device makers

What this record shows

The money is spread across several categories — grants (57.9%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Medtronic at 47.3% of the total. Reporting peaked in 2020 at $47,153 and has fallen 93.5% since, to $3,075 in 2025.

$69,509in general payments, 2019–2025

Across 292 payments — averaging $238.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$33K
  • Boston Scientific$17K
  • Biotronik Inc.$10K
  • Abbott$9K
  • Biosense Webster, Inc.$559
  • Boehringer Ingelheim$223
  • plus $888 from 16 others

What the payments were for

  • Grants$40,24558%
  • Travel & lodging$19,89729%
  • Food & beverage$8,99313%
  • Education$3751%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$69,509 in reported general payments places this provider in the 80th percentile of 90 clinical cardiac electrophysiology providers in Virginia.

See all clinical cardiac electrophysiology providers in Virginia

Medicare billing

Part B allowed, 2024
$325,790
Medicare patients
1,506
Services billed
3,310

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban237$308,763
XareltoRivaroxaban45$59,828
MultaqDronedarone Hcl31$49,810
EntrestoSacubitril/Valsartan12$20,657
Amiodarone Hcl110$6,995
Metoprolol Succinate209$3,820
Dofetilide23$2,104
Dabigatran EtexilateDabigatran Etexilate Mesylate13$1,762
Flecainide Acetate40$1,213
Diltiazem 24hr Er (Cd)Diltiazem Hcl47$1,210
Dilt-XrDiltiazem Hcl14$467
Colchicine47$430
Carvedilol55$414
Rosuvastatin Calcium29$382
Furosemide53$345

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$68$308,763237 claims
Johnson & JohnsonXarelto$58$59,82845 claims
Sanofi-aventis U.S. LLCMultaq$14$49,81031 claims
NovartisEntresto$79$20,65712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 90 clinical cardiac electrophysiology providers in Virginia.

Other clinical cardiac electrophysiology in Winchester

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →